收费全文 | 135篇 |
免费 | 8篇 |
国内免费 | 2篇 |
耳鼻咽喉 | 1篇 |
儿科学 | 1篇 |
妇产科学 | 3篇 |
基础医学 | 19篇 |
口腔科学 | 1篇 |
临床医学 | 11篇 |
内科学 | 49篇 |
皮肤病学 | 5篇 |
神经病学 | 5篇 |
特种医学 | 21篇 |
外科学 | 15篇 |
综合类 | 2篇 |
预防医学 | 2篇 |
眼科学 | 1篇 |
药学 | 8篇 |
肿瘤学 | 1篇 |
2023年 | 2篇 |
2022年 | 8篇 |
2021年 | 7篇 |
2020年 | 4篇 |
2019年 | 3篇 |
2018年 | 9篇 |
2017年 | 3篇 |
2016年 | 11篇 |
2015年 | 7篇 |
2014年 | 5篇 |
2013年 | 21篇 |
2012年 | 25篇 |
2011年 | 17篇 |
2010年 | 6篇 |
2009年 | 3篇 |
2008年 | 1篇 |
2007年 | 5篇 |
2006年 | 3篇 |
2005年 | 4篇 |
2004年 | 1篇 |
Research design and methods: The single-center, open-label, randomized, three-period, three-sequence, reference-replicated, cross-over study included 38 healthy subjects under fed conditions. In each study period (separated by a 14-day washout), a single oral dose of the test (T) or reference (R) product was administered. Blood samples were collected at pre-dose and up to 72.0 h after administration. The calculated pharmacokinetic parameters, based on the plasma concentrations of itraconazole and hydroxy itraconazole, were AUC0-72h, AUC0-∝, Cmax, Tmax, T1/2 and Kel.
Results: The 90% CI for the test/reference geometric means ratio for the parent compound, itraconazole, was in the range from 85.29% to 116.07% for AUC0-72h. Since the coefficient of variation (CV) for the reference product was 44.95% for Cmax, the 90% CI for this parameter for itraconazole was 93.49–133.78%, which was within the proposed limits of the EMA for bioequivalence of 72.15–138.59%. During the study, 4 subjects encountered a total of 14 mild adverse events.
Conclusions: The use of the reference-scaling approach with 3-period design (TRR, RTR, and RRT) was an efficient way to demonstrate that two commercially available oral itraconazole formulations met the predetermined bioequivalence criteria. 相似文献